Terms: = Prostate cancer AND PALB2, ENSG00000083093, 79728 AND Prognosis
4 results:
1. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract] [Full Text] [Related]
2. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract] [Full Text] [Related]
3. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract] [Full Text] [Related]
4. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract] [Full Text] [Related]
